Takeda Wins Reconsidered U.K. Coverage Of Mepact Bone-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals won a reversal of sorts of a negative decision in the United Kingdom on of its Mepact (mifamurtide) for treating bone cancer